Ophthalmology

Brolucizumab superior to PRP for visual outcomes and PDR regression

In CONDOR, 689 treatment-naïve PDR patients were randomized 1:1 to brolucizumab 6 mg or PRP and followed for 96 weeks. At week 54, brolucizumab improved BCVA versus PRP (mean +0.2 vs -4.2 letters; difference 4.4; 95% CI, 2.4-6.4; P < .001). More brolucizumab-treated eyes had no PDR at week 54 compared with PRP (63.6% vs 22.4%; difference 39.4; P < .001). Ocular adverse events were less frequent with brolucizumab than PRP (34.3% vs 49.1%), though intraocular inflammation details are truncated in the abstract. 1

DSDO lenses modestly outperform DIMS and suppress physiologic axial growth

This prospective multicenter real-world study followed 1541 children and adolescents using DSDO or DIMS lenses, or no correction if non-myopic. In myopes, axial elongation was lower with DSDO versus DIMS at 6 months (0.07 vs 0.09 mm; P = 0.026) and 12 months (0.17 vs 0.19 mm; P = 0.019). Greater benefit was observed in children aged ≤10 years and in low-myopia subgroups, emphasizing early individualized prescribing. In non-myopes, DSDO lenses reduced physiologic axial growth versus untreated controls at 12 months (0.18 vs 0.29 mm; P = 0.01), especially in mild hyperopia or emmetropia. 2

GLP-1 receptor agonists associated with fewer systemic and ocular events in DR

Using TriNetX data, 173,216 adults with T2D and DR were analyzed, with 30,613 GLP-1 RA users after propensity matching. GLP-1 RA use was associated with reduced myocardial infarction, coronary revascularization, heart failure exacerbation, and ischemic stroke risks over two years. Risks of lower extremity amputation, acute kidney injury, and renal replacement therapy were also lower in GLP-1 RA users. Progression to proliferative DR, retinal vein occlusion, and neovascular glaucoma was reduced, while retinal artery occlusion and NAION showed no clear association. 3